Pfizer mRNA Influenza Vaccine ‘Failed’ in Clinical Trial Among Seniors: FDA Commissioner

‘We’re not just going to rubberstamp new products that don’t work, that fail in a clinical trial,’ Dr. Marty Makary said.

A woman walks by Pfizer's headquarters in New York City, in this file image. Kena Betancur/AFP via Getty Images

Pfizer’s experimental influenza vaccine will not receive approval absent new data proving it protects seniors against the flu, the commissioner of the Food and Drug Administration suggested in a new interview.

The messenger ribonucleic acid (mRNA) shot “failed in seniors,” Dr. Marty Makary, the FDA commissioner, said during an appearance on Nov. 29 on Fox News. “The trial showed zero benefit.”